Treprostinil for the treatment of pulmonary arterial hypertension

Fernando Torres, Lewis J. Rubin

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Pulmonary arterial hypertension (PAH) is a progressive and fatal disease characterized by increasing pulmonary vascular resistance leading to right ventricular failure and death. Treprostinil is a stable prostacyclin analog approved for the treatment of PAH to improve exercise capacity. In the setting of PAH, the major pharmacological actions of treprostinil include vasodilatation of the pulmonary and systemic vascular beds, inhibition of platelet aggregation and inhibition of smooth muscle cell proliferation. Treprostinil therapy may be delivered via parenteral (subcutaneous and intravenous) or inhaled routes of administration, with oral tablets in the later stages of clinical development. In clinical trials, treprostinil has been shown to improve clinical status, functional class, exercise capacity and quality of life. Common side effects of treprostinil therapy include headache, flushing, jaw pain, diarrhea, and for subcutaneous administration, infusion site pain or reaction. This article provides an overview of treprostinil therapy for the treatment of PAH with a focus on the available efficacy and safety data for parenteral, inhaled and oral administration.

Original languageEnglish (US)
Pages (from-to)13-25
Number of pages13
JournalExpert Review of Cardiovascular Therapy
Volume11
Issue number1
DOIs
StatePublished - Jan 2013

Fingerprint

Pulmonary Hypertension
Oral Administration
Therapeutics
Subcutaneous Infusions
Pain
Epoprostenol
Jaw
Platelet Aggregation
Vasodilation
Vascular Resistance
Tablets
Smooth Muscle Myocytes
Blood Vessels
Headache
treprostinil
Diarrhea
Quality of Life
Cell Proliferation
Clinical Trials
Pharmacology

Keywords

  • prostacyclin
  • prostacyclin analog
  • prostaglandin
  • pulmonary arterial hypertension
  • treprostinil

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine

Cite this

Treprostinil for the treatment of pulmonary arterial hypertension. / Torres, Fernando; Rubin, Lewis J.

In: Expert Review of Cardiovascular Therapy, Vol. 11, No. 1, 01.2013, p. 13-25.

Research output: Contribution to journalArticle

@article{e3d3b20091c0435bab25d549148b307f,
title = "Treprostinil for the treatment of pulmonary arterial hypertension",
abstract = "Pulmonary arterial hypertension (PAH) is a progressive and fatal disease characterized by increasing pulmonary vascular resistance leading to right ventricular failure and death. Treprostinil is a stable prostacyclin analog approved for the treatment of PAH to improve exercise capacity. In the setting of PAH, the major pharmacological actions of treprostinil include vasodilatation of the pulmonary and systemic vascular beds, inhibition of platelet aggregation and inhibition of smooth muscle cell proliferation. Treprostinil therapy may be delivered via parenteral (subcutaneous and intravenous) or inhaled routes of administration, with oral tablets in the later stages of clinical development. In clinical trials, treprostinil has been shown to improve clinical status, functional class, exercise capacity and quality of life. Common side effects of treprostinil therapy include headache, flushing, jaw pain, diarrhea, and for subcutaneous administration, infusion site pain or reaction. This article provides an overview of treprostinil therapy for the treatment of PAH with a focus on the available efficacy and safety data for parenteral, inhaled and oral administration.",
keywords = "prostacyclin, prostacyclin analog, prostaglandin, pulmonary arterial hypertension, treprostinil",
author = "Fernando Torres and Rubin, {Lewis J.}",
year = "2013",
month = "1",
doi = "10.1586/erc.12.160",
language = "English (US)",
volume = "11",
pages = "13--25",
journal = "Expert Review of Cardiovascular Therapy",
issn = "1477-9072",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - Treprostinil for the treatment of pulmonary arterial hypertension

AU - Torres, Fernando

AU - Rubin, Lewis J.

PY - 2013/1

Y1 - 2013/1

N2 - Pulmonary arterial hypertension (PAH) is a progressive and fatal disease characterized by increasing pulmonary vascular resistance leading to right ventricular failure and death. Treprostinil is a stable prostacyclin analog approved for the treatment of PAH to improve exercise capacity. In the setting of PAH, the major pharmacological actions of treprostinil include vasodilatation of the pulmonary and systemic vascular beds, inhibition of platelet aggregation and inhibition of smooth muscle cell proliferation. Treprostinil therapy may be delivered via parenteral (subcutaneous and intravenous) or inhaled routes of administration, with oral tablets in the later stages of clinical development. In clinical trials, treprostinil has been shown to improve clinical status, functional class, exercise capacity and quality of life. Common side effects of treprostinil therapy include headache, flushing, jaw pain, diarrhea, and for subcutaneous administration, infusion site pain or reaction. This article provides an overview of treprostinil therapy for the treatment of PAH with a focus on the available efficacy and safety data for parenteral, inhaled and oral administration.

AB - Pulmonary arterial hypertension (PAH) is a progressive and fatal disease characterized by increasing pulmonary vascular resistance leading to right ventricular failure and death. Treprostinil is a stable prostacyclin analog approved for the treatment of PAH to improve exercise capacity. In the setting of PAH, the major pharmacological actions of treprostinil include vasodilatation of the pulmonary and systemic vascular beds, inhibition of platelet aggregation and inhibition of smooth muscle cell proliferation. Treprostinil therapy may be delivered via parenteral (subcutaneous and intravenous) or inhaled routes of administration, with oral tablets in the later stages of clinical development. In clinical trials, treprostinil has been shown to improve clinical status, functional class, exercise capacity and quality of life. Common side effects of treprostinil therapy include headache, flushing, jaw pain, diarrhea, and for subcutaneous administration, infusion site pain or reaction. This article provides an overview of treprostinil therapy for the treatment of PAH with a focus on the available efficacy and safety data for parenteral, inhaled and oral administration.

KW - prostacyclin

KW - prostacyclin analog

KW - prostaglandin

KW - pulmonary arterial hypertension

KW - treprostinil

UR - http://www.scopus.com/inward/record.url?scp=84871569248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871569248&partnerID=8YFLogxK

U2 - 10.1586/erc.12.160

DO - 10.1586/erc.12.160

M3 - Article

C2 - 23259441

AN - SCOPUS:84871569248

VL - 11

SP - 13

EP - 25

JO - Expert Review of Cardiovascular Therapy

JF - Expert Review of Cardiovascular Therapy

SN - 1477-9072

IS - 1

ER -